Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

-- Single pivotal trial to initiate later this month targets the broad patient population with two APOL1 mutations and proteinuric kidney disease –

– Pathway for accelerated approval using an interim analysis at Week 48 of eGFR slope, supported by reduction in proteinuria –

– Final analysis evaluating eGFR slope at approximately two years serves as basis for U.S. approval –